May, 2021

No. 106 (5)

2019 Impact Factor: 7.116

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma

This study investigate the prognostic impact of MYC rearrangement (MYC-R) and of extra copies of MYC (MYC-EC) in the absence of MYC-R in 88 patients with mantle cell lymphoma. Patients with MYC-R had a very aggressive clinical course and a poor prognosis, while those with MYC-EC had a prognosis intermediate between that of patients with MYC-R and that of patients with normal MYC. These results suggest that patients with different MYC status may need different treatment strategies.

Lifu Wang et al.


Cytoskeletal-based mechanisms differently regulate in vivo and in vitro proplatelet formation

The morphology of proplatelets (PPT) observed in vitro differs greatly from that observed in vivo. Contrary to in vitro PPT formation, the mechanisms of native PPT formation are poorly understood. This study revealed that PPT elongation in living mice is in equilibrium between protrusion and retraction forces mediated by myosin-IIA. Moreover, the role of microtubules differs between in vitro PPT and native PPT, being essential in vitro, but less critical in vivo.

Alicia Bornert et al.


A zebrafish model for HAX1-associated congenital neutropenia

Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signaling pathway. This model will serve as an in vivo platform to identify tailored therapeutic strategies for congenital neutropenia

Larissa Doll et al.

Case Report

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy

Two patients with refractory large B-cell lymphoma received CAR T-cell therapy. Both developed acute leucoencephalomyelopathy and quadriparesis, which was promptly reversed by prompt initiation of high-dose corticosteroids. Despite this treatment, both patients attained durable complete lymphoma response. Thus, corticosteroids are unlikely to affect CAR T-cell efficacy when used for management of severe toxicities.

Ranjit Nair et al.